Health Canada's DSEN advances
Canada's Health Minister, Leona Aglukkaq, says the government is continuing to support the Drug Safety and Effectiveness Network, first announced in July 2008.
"Canadians can be confident that this government is taking the steps necessary to ensure that our drug safety system remains one of the best in the world," she claims, adding that the DSEN "complements Canada's rigorous pre-testing of new drugs by studying how Canadians respond over time to already-approved drugs. The results will help in decision-making and enhance overall consumer safety."
The Network, she explained, will enable more national research on the safety and effectiveness of drugs used by Canadians. It will:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze